



HelixBind, Inc

HELIXBIND

Contact:
Alon Singer

Location:
Marlborough, MA

Email:
asinger@helixbind.com

Tel:
508.460.1028

Website:
<http://www.helixbind.com>



Company Profile

Industry Sector: Medical Diagnostics

Company Overview: HelixBind is developing a platform for the rapid detection and identification of bloodstream infections (BSIs) directly from whole-blood in two hours (without culturing). BSIs leading to septicemia account for almost 50% of all hospital deaths in the United States despite being treatable with existing drugs, as current diagnostic tests require days where physicians must act within hours.

HelixBind was founded in 2013 and is financed by both multiple SBIR awards and Angel investments. The company has completed development of the technology and has filed patent applications to cover a range of critical inventions. In a pilot clinical study, the test demonstrated 96% sensitivity, 90% specificity versus culture performed by the hospital's microbiology lab.

Target Market(s): Hospitals



Key Value Drivers

Technology*: Sample-in / Results-out MDx for sepsis.

Competitive Advantages:

- Time to result <2 hours
- Broad panel encompassing 21 pathogens simultaneously
- <10 CFU/ml sensitivity across entire panel
- Fully automated and integrated
- Single-use cassette, minimal hands-on time
- Readily integrated into current workflow

Plan & Strategy: HelixBind's platform includes a small, bench-top, analyzer; easily deployed in hospital labs of any size, and single-use test cassettes.



Management

Leadership:

CEO - Alon Singer, PhD

Dir. of Product Dev. – Ranjit Prakash

Manager of Assay Dev. Jork Nolling, PhD

Advisory Board:

Yi-Wei Tang, MD – Chief of Clinical Micro at MSKCC

David Steinmiller – Founder of Clarus MDx

Ethan Mollick, PhD – Prof. UPenn



Product Pipeline

1. Product One: Pathogen Identification.

Automated identification of over 92% of all BSIs directly from patient specimens in two hours.

2. Product Two: Antibiotic Resistance Detection.

Automated identification of key resistance genes using the HelixBind platform

3. Product Three: Antibiotic Performance Assessment.

Monitoring of antimicrobial treatment effectiveness